Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CERo Therapeutics HoldingsCERO -12.75% EV-to-FCF is -0.52 as of Jul. 14, 2026. The stock has 2 warning signs investors should review. Among 335 Biotechnology companies, CERo Therapeutics Holdings ranks worse than 298507.16% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CERo Therapeutics Holdings's Enterprise Value is $7.55 Mil.
CERo Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-14.40 Mil. Therefore, CERo Therapeutics Holdings's EV-to-FCF for today is -0.52.
The historical rank and industry rank for CERo Therapeutics Holdings's EV-to-FCF or its related term are showing as below:
CERO'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.54 Med: 0 Max: 0
Current: -0.52
CERO's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs CERO: -0.52
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CERo Therapeutics Holdings's PE Ratio (TTM) for today is calculated as:
CERo Therapeutics Holdings's share price for today is $0.013.
CERo Therapeutics Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-73.306.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CERo Therapeutics Holdings EV-to-FCF Related Terms
CERo Therapeutics Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CERo Therapeutics Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CERo Therapeutics Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CERo Therapeutics Holdings's EV-to-FCF falls into.
CERo Therapeutics Holdings's current Enterprise Value is $7.55 Mil.
CERo Therapeutics Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.40 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERo Therapeutics Holdings (CERO) has a EV-to-FCF of -0.52 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CERo Therapeutics Holdings and its competitors. According to the industry distribution chart, CERo Therapeutics Holdings ranks #999999 out of 335 companies in the Biotechnology industry.
Is CERo Therapeutics Holdings' EV-to-FCF too high?
CERo Therapeutics Holdings' current EV-to-FCF is -0.52. Based on the distribution chart, CERo Therapeutics Holdings ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CERo Therapeutics Holdings' EV-to-FCF compare to WINT and LIPO?
According to the Biotechnology industry distribution chart, CERo Therapeutics Holdings ranks #999999 out of 335 companies for EV-to-FCF. This places CERo Therapeutics Holdings in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CERo Therapeutics Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CERo Therapeutics Holdings's current EV-to-FCF is -0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current EV-to-FCF of -0.52. The current EV-to-FCF is -0.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current EV-to-FCF is -0.52 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERO has been successfully added to your 
